Showing paper detailed information
Citation Information
Clin Exp Med. 2019 Nov;19(4):505-513. doi: 10.1007/s10238-019-00566-7. Epub 2019 Jul 1.
Serum lipidome screening in patients with stage I non-small cell lung cancer.
Klupczynska A, Plewa S, Kasprzyk M, Dyszkiewicz W, Kokot ZJ, Matysiak J.
Analytical methods | ||
|---|---|---|
| Comparative study | #1 | |
| Chromatography | flow infusion | |
| Ion source | – | |
| Positive/Negative mode | – | |
| Mass analyzer | QTRAP | |
| Identification level | MS/MS | |
Sample information | ||
|---|---|---|
| Comparative study | #1 | |
| Country | Poland | |
| Specimen | serum | |
| Marker function | diagnosis | |
| Participants(Case) | Cancer type | adenocarcinoma, squamous cell carcinoma |
| Stage | I | |
| Number | 20 | |
| Gender (M,F) | 11, 9 | |
| Mean age (range) (M,F) | 62 ± 5 | |
| Smoking status | smoker, non-smoker | |
| Participants(Control) | Type | noncancerous lung diseases |
| Number | 20 | |
| Gender (M,F) | 8, 16 | |
| Mean age (range) (M,F) | 63 ± 6 | |
| Smoking status | smoker, non-smoker | |
Data processing and metabolite identification | |
|---|---|
| Data processing software | Analyst |
| Database search | – |
Statistical analysis | |
|---|---|
| Differential analysis method | Wilcoxon rank-sum test |
| Classification method | ROC analysis |
| Survival analysis method | – |
Lung cancer-related metabolites identified in the paper
| Metabolite | Author-emphasized biomarkers | Mean concentration (case) | Mean concentration (control) | Fold change (case/control) | P-value | FDR | VIP |
|---|---|---|---|---|---|---|---|
| phosphatidylcholine diacyl C40:2 | V | 0.24 ± 0.09 | 0.15 ± 0.04 | 1.88 | 3.81e-03 | 0.05 | – |
| lysophosphatidylcholine acyl C26:1 | V | 0.28 ± 0.07 | 0.18 ± 0.06 | 1.52 | 8.30e-04 | 0.04 | – |
| phosphatidylcholine diacyl C42:4 | V | 0.46 ± 0.22 | 0.26 ± 0.12 | 1.79 | 1.74e-03 | 0.05 | – |
| phosphatidylcholine acyl-alkyl C44:3 | V | 0.52 ± 0.21 | 0.33 ± 0.11 | 1.58 | 3.22e-03 | 0.05 | – |
| lysophosphatidylcholine acyl C26:0 | V | 0.53 ± 0.14 | 0.31 ± 0.14 | 1.71 | 1.10e-04 | 0.01 | – |
| phosphatidylcholine acyl-alkyl C42:1 | V | 0.69 ± 0.14 | 0.53 ± 0.13 | 1.57 | 2.73e-03 | 0.05 | – |
| phosphatidylcholine diacyl C34:4 | V | 0.93 ± 0.40 | 1.44 ± 0.43 | 0.65 | 1.62e-03 | 0.05 | – |
| Metabolite | Author-emphasized biomarkers | Cutoff value | AUROC (95%CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
|---|---|---|---|---|---|---|
| phosphatidylcholine diacyl C40:2 | V | – | 0.80 (0.64-0.92) | – | – | – |
| lysophosphatidylcholine acyl C26:1 | V | – | 0.84 (0.68-0.95) | – | – | – |
| phosphatidylcholine diacyl C42:4 | V | – | 0.81 (0.65-0.93) | – | – | – |
| phosphatidylcholine acyl-alkyl C44:3 | V | – | 0.80 (0.62-0.92) | – | – | – |
| lysophosphatidylcholine acyl C26:0 | V | – | 0.87 (0.73-0.96) | – | – | – |
| phosphatidylcholine acyl-alkyl C42:1 | V | – | 0.80 (0.64-0.94) | – | – | – |
| phosphatidylcholine diacyl C34:4 | V | – | 0.82 (0.65-0.94) | – | – | – |
Paper graphical summary
